Harnessing Microbial Peptides for Drug Discovery PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Harnessing Microbial Peptides for Drug Discovery PDF full book. Access full book title Harnessing Microbial Peptides for Drug Discovery by Conor Pulliam. Download full books in PDF and EPUB format.
Author: Conor Pulliam
Publisher: American Chemical Society
ISBN: 0841296332
Category : Medical
Languages : en
Pages : 151
Get Book Here
Book Description
Harnessing Microbial Peptides for Drug Discovery offers a concise introduction for researchers new to antimicrobial peptides. This primer provides essential information to navigate the current scientific literature on bacterial peptide discovery. Chapter 1 surveys foundational background information on microbes’ biosynthetic potentials and two major superfamilies of bioactive peptides: ribosomally synthesized and post-translationally modified peptides (RiPPs) and non-ribosomal peptides (NRPs). Chapter 2 gives a brief history of traditional methods of discovery of bioactive peptides, followed by an in-depth explanation of several current and emerging methods. These current and emerging methods are bioinformatic tools applied to genome-transcriptome sequences, molecular cloning of gene constructs into plasmids for expression in heterologous hosts, and isolation and characterization of peptides via HPLC, MS, and NMR. The final chapter, Chapter 3, uses several examples of bioactive peptides to explore the diverse chemistry and biosynthesis microbes employed to produce these versatile biomolecules. In addition, this primer contains useful pedagogical features to enhance the reading experience: a pop-up glossary for seamless learning, "Insider Q&A" video interviews with expert insights, "That's a Wrap" summaries at the end of each chapter, and "Read These Next" references to aid in transitioning into the literature. Readers will gain valuable insight into peptide therapeutic discovery and avoid the major headaches that usually occur when starting a new field.
Author: Conor Pulliam
Publisher: American Chemical Society
ISBN: 0841296332
Category : Medical
Languages : en
Pages : 151
Get Book Here
Book Description
Harnessing Microbial Peptides for Drug Discovery offers a concise introduction for researchers new to antimicrobial peptides. This primer provides essential information to navigate the current scientific literature on bacterial peptide discovery. Chapter 1 surveys foundational background information on microbes’ biosynthetic potentials and two major superfamilies of bioactive peptides: ribosomally synthesized and post-translationally modified peptides (RiPPs) and non-ribosomal peptides (NRPs). Chapter 2 gives a brief history of traditional methods of discovery of bioactive peptides, followed by an in-depth explanation of several current and emerging methods. These current and emerging methods are bioinformatic tools applied to genome-transcriptome sequences, molecular cloning of gene constructs into plasmids for expression in heterologous hosts, and isolation and characterization of peptides via HPLC, MS, and NMR. The final chapter, Chapter 3, uses several examples of bioactive peptides to explore the diverse chemistry and biosynthesis microbes employed to produce these versatile biomolecules. In addition, this primer contains useful pedagogical features to enhance the reading experience: a pop-up glossary for seamless learning, "Insider Q&A" video interviews with expert insights, "That's a Wrap" summaries at the end of each chapter, and "Read These Next" references to aid in transitioning into the literature. Readers will gain valuable insight into peptide therapeutic discovery and avoid the major headaches that usually occur when starting a new field.
Author: Robert A. Britton
Publisher: John Wiley & Sons
ISBN: 1683673026
Category : Medical
Languages : en
Pages : 725
Get Book Here
Book Description
Examining the enormous potential of microbiome manipulation to improve health Associations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. Bugs as Drugs provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease. In Bugs as Drugs, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include: How well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response. The use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage. The association of specific microbiota composition with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis. Fecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes. Because systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted. If you are looking for online access to the latest clinical microbiology content, please visit www.wiley.com/learn/clinmicronow.
Author: National Research Council
Publisher: National Academies Press
ISBN: 0309169712
Category : Science
Languages : en
Pages : 130
Get Book Here
Book Description
Dramatic developments in understanding the fundamental underpinnings of life have provided exciting opportunities to make marine bioproducts an important part of the U.S. economy. Several marine based pharmaceuticals are under active commercial development, ecosystem health is high on the public's list of concerns, and aquaculture is providing an ever greater proportion of the seafood on our tables. Nevertheless, marine biotechnology has not yet caught the public's, or investor's, attention. Two workshops, held in October 1999 and November 2001 at the National Academies, were successful in highlighting new developments and opportunities in environmental and biomedical applications of marine biotechnology, and also in identifying factors that are impeding commercial exploitation of these products. This report includes a synthesis of the 2001 sessions addressing drug discovery and development, applications of genomics and proteomics to marine biotechnology, biomaterials and bioengineering, and public policy and essays contributed by the workshop speakers.
Author: Yanyan Li
Publisher: Springer
ISBN: 1493910108
Category : Medical
Languages : en
Pages : 113
Get Book Here
Book Description
Lasso peptides form a growing family of fascinating ribosomally-synthesized and post-translationally modified peptides produced by bacteria. They contain 15 to 24 residues and share a unique interlocked topology that involves an N-terminal 7 to 9-residue macrolactam ring where the C-terminal tail is threaded and irreversibly trapped. The ring results from the condensation of the N-terminal amino group with a side-chain carboxylate of a glutamate at position 8 or 9, or an aspartate at position 7, 8 or 9. The trapping of the tail involves bulky amino acids located in the tail below and above the ring and/or disulfide bridges connecting the ring and the tail. Lasso peptides are subdivided into three subtypes depending on the absence (class II) or presence of one (class III) or two (class I) disulfide bridges. The lasso topology results in highly compact structures that give to lasso peptides an extraordinary stability towards both protease degradation and denaturing conditions. Lasso peptides are generally receptor antagonists, enzyme inhibitors and/or antibacterial or antiviral (anti-HIV) agents. The lasso scaffold and the associated biological activities shown by lasso peptides on different key targets make them promising molecules with high therapeutic potential. Their application in drug design has been exemplified by the development of an integrin antagonist based on a lasso peptide scaffold. The biosynthesis machinery of lasso peptides is therefore of high biotechnological interest, especially since such highly compact and stable structures have to date revealed inaccessible by peptide synthesis. Lasso peptides are produced from a linear precursor LasA, which undergoes a maturation process involving several steps, in particular cleavage of the leader peptide and cyclization. The post-translational modifications are ensured by a dedicated enzymatic machinery, which is composed of an ATP-dependent cysteine protease (LasB) and a lactam synthetase (LasC) that form an enzymatic complex called lasso synthetase. Microcin J25, produced by Escherichia coli AY25, is the archetype of lasso peptides and the most extensively studied. To date only around forty lasso peptides have been isolated, but genome mining approaches have revealed that they are widely distributed among Proteobacteria and Actinobacteria, particularly in Streptomyces, making available a rich resource of novel lasso peptides and enzyme machineries towards lasso topologies.
Author: Kiran Bala
Publisher: Springer Nature
ISBN: 9819711525
Category :
Languages : en
Pages : 574
Get Book Here
Book Description
Author: J. Mulzer
Publisher: Springer Science & Business Media
ISBN: 3662040425
Category : Medical
Languages : en
Pages : 363
Get Book Here
Book Description
Natural Products have been important sources of useful drugs from prehistoric times to the present. This book gives an overview about this field and provides important recent contributions to the discovery of new drugs generated by research on natural products. Total synthesis of natural products with interesting biological activities is paving the way for the preparation of new and improved analogs. The methods of combinatorial chemistry permit the selection of the best drug from a large number of candidates. Beyond synthesis and evaluation of organic molecules a number of new bioorganic methods are coming to the fore and will be discucced in this isue of the ERnst schering Research Foundation workshop proceedings.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309458390
Category : Science
Languages : en
Pages : 133
Get Book Here
Book Description
The 21st century has witnessed a complete revolution in the understanding and description of bacteria in eco- systems and microbial assemblages, and how they are regulated by complex interactions among microbes, hosts, and environments. The human organism is no longer considered a monolithic assembly of tissues, but is instead a true ecosystem composed of human cells, bacteria, fungi, algae, and viruses. As such, humans are not unlike other complex ecosystems containing microbial assemblages observed in the marine and earth environments. They all share a basic functional principle: Chemical communication is the universal language that allows such groups to properly function together. These chemical networks regulate interactions like metabolic exchange, antibiosis and symbiosis, and communication. The National Academies of Sciences, Engineering, and Medicine's Chemical Sciences Roundtable organized a series of four seminars in the autumn of 2016 to explore the current advances, opportunities, and challenges toward unveiling this "chemical dark matter" and its role in the regulation and function of different ecosystems. The first three focused on specific ecosystemsâ€"earth, marine, and humanâ€"and the last on all microbiome systems. This publication summarizes the presentations and discussions from the seminars.
Author: Ved Srivastava
Publisher: Royal Society of Chemistry
ISBN: 1782627324
Category : Medical
Languages : en
Pages : 589
Get Book Here
Book Description
With potentially high specificity and low toxicity, biologicals offer promising alternatives to small-molecule drugs. Peptide therapeutics have again become the focus of innovative drug development efforts backed up by a resurgence of venture funds and small biotechnology companies. What does it take to develop a peptide-based medicine? What are the key challenges and how are they overcome? What are emerging therapeutics for peptide modalities? This book answers these questions with a holistic story from molecules to medicine, combining the themes of design, synthesis and clinical applications of peptide-based therapeutics and biomarkers. Chapters are written and edited by leaders in the field from industry and academia and they cover the pharmacokinetics of peptide therapeutics, attributes necessary for commercially successful metabolic peptides, medicinal chemistry strategies for the design of peptidase-resistant peptide analogues, disease classes for which peptide therapeutic are most relevant, and regulatory issues and guidelines. The critical themes covered provide essential background information on what it takes to develop peptide-based medicine from a chemistry perspective and views on the future of peptide drugs. This book will be a valuable resource not only as a reference book for the researcher engaged in academic and pharmaceutical setting, from basic research to manufacturing and from organic chemistry to biotechnology, but also a valuable resource to graduate students to understand discovery and development process for peptide-based medicine.
Author: Se-Kwon Kim
Publisher: John Wiley & Sons
ISBN: 3527665277
Category : Science
Languages : en
Pages : 558
Get Book Here
Book Description
Deliberately breaking with the classical biology-centered description of marine organisms and their products, this reference emphasizes microbial technology over basic biology, setting it apart from its predecessors. As such, it systematically covers the technology behind high-value compounds for use as pharmaceuticals, nutraceuticals or cosmetics, from prospecting to production issues. Following a definition of the field, the book goes on to address all industrially important aspects of marine microbial biotechnology. The first main part contains a description of the major production organisms, from archaebacteria to cyanobacteria to algae and symbionts, including their genetic engineering. The remaining four parts look at commercially important compounds produced by these microorganisms together with their applications. Throughout, the emphasis is on technological considerations, and the future potential of these organisms or compound classes is discussed. A valuable and forward-looking resource for innovative biotechnologists in industry as well as in academia.
Author: Harald H. H. W. Schmidt
Publisher: Springer Nature
ISBN: 3030685101
Category : Medical
Languages : en
Pages : 425
Get Book Here
Book Description
Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term ‘oxidative stress’ is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
